Cristina Fillat

Research group

Gene therapy and cancer Group leader (R4)

cfillat@recerca.clinic.cat 0000-0002-0801-3338

Follow it on:

The Researchgate of Cristina . This link opens in a new tab.

Featured publications

Codon Usage and Adenovirus Fitness: Implications for Vaccine Development

Authors:
Giménez-Roig, J; Núñez-Manchón, E; Alemany, R; Villanueva, E; Fillat, C;

Reference: Frontiers In Microbiology 2021.
Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: Boosting the efficacy of intravenously administered therapeutic adenoviruses

Authors:
Brugada-Vilà P; Cascante A; Lázaro MÁ; Castells-Sala C; Fornaguera C;

Rovira-Rigau M; Albertazzi L; Borros S; Fillat C.

Reference: Theranostics 2020.
DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth

Authors:
Luna, Jeroni; Boni, Jacopo; Cuatrecasas, Miriam; Bofill-De Ros, Xavier; Nunez-Manchon, Estela;

Gironella, Meritxell; Vaquero, Eva C; Arbones, Maria L; de la Luna, Susana; Fillat, Cristina.

Reference: Gut 2019.
Bioselection Reveals miR-99b and miR-485 as Enhancers of Adenoviral Oncolysis in Pancreatic Cancer.

Authors:
Rovira-Rigau M; Raimondi G; Marín MÁ; Gironella M; Alemany R;

Fillat C .

Reference: Molecular Therapy 2019.
Translational reprogramming in tumour cells can generate oncoselectivity in viral therapies

Authors:
Villanueva, Eneko; Navarro, Pilar; Rovira-Rigau, Maria; Sibilio, Annarita; Mendez, Raul;

Fillat, Cristina.

Reference: Nature Communications 2017.
AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-KB mediated uPAR activation

Authors:
Victoria Maliandi, Maria; Mato-Berciano, Ana; Sobrevals, Luciano; Roue, Gael; Jose, Anabel;

Fillat, Cristina.

Reference: Molecular Cancer 2015.
A genetic fiber modification to achieve matrix-metalloprotease-activated infectivity of oncolytic adenovirus

Authors:
Jose, Anabel; Rovira-Rigau, Maria; Luna, Jeroni; Gimenez-Alejandre, Marta; Vaquero, Eva;

Garcia de la Torre, Beatriz; Andreu, David; Alemany, Ramon; Fillat, Cristina.

Reference: Journal Of Controlled Release 2014.
MiR-148a-and miR-216a-regulated oncolytic adenoviruses targeting pancreatic tumors attenuate tissue damage without perturbation of miRNA activity

Authors:
Bofill-de Ros, Xavier; Gironella, Meritxell; Fillat, Cristina;

Reference: Molecular Therapy 2014.
Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates dependent defects in the Ts65Dn mouse model of Down syndrome

Authors:
Altafaj, Xavier; Martin, Eduardo D; Ortiz-Abalia, Jon; Valderrama, Aitana; Lao-Peregrin, Cristina;

Dierssen, Mara; Fillat, Cristina.

Reference: Neurobiology Of Disease 2013.
Targeting Dyrk1A with AAVshRNA Attenuates Motor Alterations in TgDyrk1A, a Mouse Model of Down Syndrome

Authors:
Ortiz-Abalia, Jon; Sahun, Ignasi; Altafaj, Xavier; Andreu, Nuria; Estivill, Xavier;

Dierssen, Mara; Fillat, Cristina.

Reference: American Journal Of Human Genetics 2008.

Featured Projects

Immunological incompatibility as a basis for cancer curing and vaccination - ULISES

Principal investigator: Cristina Fillat Fonts

Funder: European Commission

Code: 899708

Duration: 01/10/2020 - 02/10/2023

Web: https://ulises-project.eu/
Adeno-associated viral gene therapy with AAV9-GCDH to correct glutaric aciduria type I in Gcdh -/- mice.

Principal investigator: Cristina Fillat Fonts

Funder: Fundación Ramón Areces

Code: CIVP19S8539

Duration: 03/04/2019 - 30/09/2022
Adenovirus oncoliticos protegidos frente anticuerpos neutralizantes y optimizados para la expresion de transgenes y reprogramacion del estroma de tumores pancreaticos

Principal investigator: Cristina Fillat Fonts

Funder: Ministerio de Economia y Competitividad (MINECO)

Code: BIO2017-89745-CR-2-R

Duration: 01/01/2018 - 01/01/2020
Grup de Recerca Reconegut: teràpia gènica i neoplàsia pancreàtica

Principal investigator: Cristina Fillat Fonts

Funder: Generalitat de Catalunya

Code: 2017-SGR-00861

Duration: 01/01/2017 - 30/09/2021

Cristina Fillat

Research group

Featured publications

Featured Projects

Immunological incompatibility as a basis for cancer curing and vaccination - ULISES

Adeno-associated viral gene therapy with AAV9-GCDH to correct glutaric aciduria type I in Gcdh -/- mice.

Adenovirus oncoliticos protegidos frente anticuerpos neutralizantes y optimizados para la expresion de transgenes y reprogramacion del estroma de tumores pancreaticos

Grup de Recerca Reconegut: teràpia gènica i neoplàsia pancreàtica

Subscribe to the Newsletter of Clínic